Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(23 sites)
Belgium
Ghent University Hospital, Ghent France
Hopital Robert Debre, Paris Armand Trousseau Hospital, Paris Centre Hospitalier Universitaire de Poitiers, Poitiers Chu de Rennes - Hospital Sud, Rennes Italy
Aou Policlinico S. Orsola-Malpighi, Bologna Asst Degli Spedali Civili Di Brescia, Brescia Ospedale Pediatrico G. Gaslini, Genova Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano, Milan University of Milano Bicocca, Monza Aorn Santobono Pausilipon, Naples Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo, Pavia Ospedale Pediatrico Bambino Gesu Irccs, Rome A.O.U Citta Della Salute E Della Scienza Di Torino Presidio Ospedaliero Infantile Regina Margherita, Torino Netherlands
Princess Maxima Center For Pediatric Oncology, Utrecht Spain
Hospital General Universitario Vall D Hebron, Barcelona Hospital Sant Joan de Deu de Manresa, Barcelona Hospital Infantil Unversitario Nino Jesus, Madrid Hospital Universitari I Politecnic La Fe, Valencia Sweden
Karolinska University Hospital Solna, Stockholm United Kingdom
Royal Hospital For Sick Children Yorkhill Glasgow, Glasgow Alder Hey Childrens Nhs Foundation Trust, Liverpool The Royal Marsden Nhs Foundation Trust - Sutton, Sutton